News|Articles|September 10, 2026

Which Lung Cancer Presentations Will Move the Needle at WCLC 2026?

Fact checked by: Tim Cortese

Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.

The IASLC 2026 World Conference on Lung Cancer (WCLC) will deliver a new wave of data on several facets of the lung cancer paradigm. Novel findings on modalities such as antibody drug conjugates, targetable mutations in markers like HER2, and other relevant therapeutic areas may pose implications for all corners of thoracic oncology.

Related to this article

ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.

October 22nd, 2026

ESMO 2026: The Presentations That May Transform The Lung Cancer Paradigm

ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.

October 26th, 2026

Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

October 26th, 2026

Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC

Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.

October 26th, 2026

Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

3d illustration of throat cancer | Image Credit: © Lars Neumann - stock.adobe.com

October 26th, 2026

ctDNA Clearance Tracks With Survival on Pembrolizumab in HPV-Negative HNSCC

In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic castration-sensitive prostate cancer.

October 26th, 2026

FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer

Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

October 26th, 2026

Pumitamig Combo Yields Activity in Metastatic Non–Small Cell Lung Cancer

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

October 26th, 2026

Omitting RT After Lumpectomy Yields 14.8% 5-Year Local Recurrence in Older Women

In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.